301. 黄斑ジストロフィー
[臨床試験数:41,薬物数:47(DrugBank:12),標的遺伝子数:12,標的パスウェイ数:66

Searched query = "Macular dystrophy", "Best disease", "Stargardt disease", "Cone dystrophy", "Cone rod dystrophy", "X-linked juvenile retinoschisis", "Central areolar choroidal dystrophy"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.

Search in Page e.g. "Phase 3", "Not recruiting", "Japan"
3 trials found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1EUCTR2018-001496-20-DE
(EUCTR)
14/05/201912/11/2018A phase II study of soraprazan in patients with Stargardt diseaseA multi-national, multi-centre, double-masked, placebo-controlled proof of concept trial to evaluate the safety and efficacy of oral soraprazan in Stargardt disease Stargardt Disease
MedDRA version: 20.1;Level: PT;Classification code 10062766;Term: Stargardt's disease;System Organ Class: 10010331 - Congenital, familial and genetic disorders;Therapeutic area: Diseases [C] - Eye Diseases [C11]
Product Name: Soraprazan
INN or Proposed INN: SORAPRAZAN
Katairo GmbHNULLAuthorised-recruitment may be ongoing or finishedFemale: yes
Male: yes
90Phase 2Netherlands;Germany;United Kingdom
2EUCTR2018-001496-20-NL
(EUCTR)
01/04/201909/05/2019A phase II study of soraprazan in patients with Stargardt diseaseA multi-national, multi-centre, double-masked, placebo-controlled proof of concept trial to evaluate the safety and efficacy of oral soraprazan in Stargardt disease Stargardt Disease;Therapeutic area: Diseases [C] - Eye Diseases [C11]Product Name: Soraprazan
INN or Proposed INN: SORAPRAZAN
Katairo GmbHNULLAuthorised-recruitment may be ongoing or finishedFemale: yes
Male: yes
90Phase 2Netherlands;United Kingdom
3EUCTR2018-001496-20-GB
(EUCTR)
21/01/201927/11/2018A phase II study of soraprazan in patients with Stargardt DiseaseA multi-national, multi-centre, double-masked, placebo-controlled proof of concept trial to evaluate the safety and efficacy of oral soraprazan in Stargardt Disease - SMR-3438 Stargardt Disease;Therapeutic area: Diseases [C] - Eye Diseases [C11]Product Name: Soraprazan
INN or Proposed INN: SORAPRAZAN
Katairo GmbHNULLAuthorised-recruitment may be ongoing or finishedFemale: yes
Male: yes
90Phase 2Netherlands;United Kingdom